Showing 1 - 5 results of 5 for search 'Eva Rettinger', query time: 0.02s Refine Results
  1. 1
    ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma

    ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma by Catrin Heim, Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Herman Kreyenberg, Halvard B. Bonig, Halvard B. Bonig, Torsten Tonn, Torsten Tonn, Winfried S. Wels, Winfried S. Wels, Winfried S. Wels, Elise Gradhand, Elise Gradhand, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Michael T. Meister, Michael T. Meister, Marian Groot Koerkamp, Marian Groot Koerkamp, Frank C. P. Holstege, Frank C. P. Holstege, Jarno Drost, Jarno Drost, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Peter Bader, Peter Bader, Michael Merker, Michael Merker, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger

    Published 2023-08-01
    Get full text
    Article
  2. 2
    Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy

    Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy by Philipp Wendel, Lisa Marie Reindl, Tobias Bexte, Leander Künnemeyer, Vinzenz Särchen, Nawid Albinger, Andreas Mackensen, Eva Rettinger, Tobias Bopp, Evelyn Ullrich

    Published 2021-03-01
    Get full text
    Article
  3. 3
    Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor

    Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor by Leonie D. H. Gossel, Catrin Heim, Lisa-Marie Pfeffermann, Laura M. Moser, Halvard B. Bönig, Thomas E. Klingebiel, Peter Bader, Winfried S. Wels, Michael Merker, Eva Rettinger

    Published 2021-03-01
    Get full text
    Article
  4. 4
    The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation

    The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma:... by Annekathrin Heinze, Annekathrin Heinze, Annekathrin Heinze, Beatrice Grebe, Beatrice Grebe, Melanie Bremm, Melanie Bremm, Sabine Huenecke, Sabine Huenecke, Tasleem Ah. Munir, Tasleem Ah. Munir, Lea Graafen, Lea Graafen, Jochen T. Frueh, Jochen T. Frueh, Michael Merker, Michael Merker, Eva Rettinger, Eva Rettinger, Jan Soerensen, Jan Soerensen, Thomas Klingebiel, Peter Bader, Peter Bader, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Claudia Cappel, Claudia Cappel

    Published 2019-12-01
    Get full text
    Article
  5. 5
    Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells

    Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells by Melanie Bremm, Lisa-Marie Pfeffermann, Claudia Cappel, Verena Katzki, Stephanie Erben, Sibille Betz, Andrea Quaiser, Michael Merker, Halvard Bonig, Michael Schmidt, Thomas Klingebiel, Peter Bader, Sabine Huenecke, Eva Rettinger

    Published 2019-05-01
    Get full text
    Article

Search Tools: